Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 2/20 | 0.55 |
| ▸ | DRD4 | P21917 | 8/20 | 0.45 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2928718 | 1.00 | ACLY (0.55) | ACLYDRD4EPHA2KDREPHB4 | |
| SCHEMBL15287543 | 0.94 | ACLY (0.49) | ACLYDRD4EPHA2KDREPHB4 | |
| SCHEMBL15287559 | 0.92 | ACLY (0.49) | ACLYDRD4EPHA2KDREPHB4 | |
| SCHEMBL4014930 | 0.91 | ACLY (0.51) | ACLYDRD4EPHA2KDREPHB4 | |
| SCHEMBL4318896 | 0.91 | ACLY (0.51) | ACLYDRD4EPHA2KDREPHB4 | |
| SCHEMBL2926088 | 0.90 | ACLY (0.49) | ACLYDRD4EPHA2KDREPHB4 | |
| SCHEMBL2931552 | 0.90 | ACLY (0.49) | ACLYDRD4EPHA2KDREPHB4 | |
| SCHEMBL15287460 | 0.90 | ACLY (0.45) | ACLYDRD4EPHA2KDREPHB4 | |
| SCHEMBL15287518 | 0.89 | ACLY (0.44) | ACLYDRD4EPHA2KDREPHB4 | |
| SCHEMBL15287481 | 0.86 | ACLY (0.42) | ACLYDRD4EPHA2KDREPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534695-B1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2010-09-29 | — | — | EP | disclosed |
| US-7560546-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1534695-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20050261496-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2005-11-24 | — | — | US | disclosed |
| EP-1534695-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040102360-A1 | Combination therapy | BARNETT STANLEY F (US) | 2004-05-27 | — | — | US | disclosed |
| WO-2004014851-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261496-A1 | Tyrosine kinase inhibitors | ABL1, JAK2, ERBB2 | ACLY 3558/4885DRD4 2379/4885EPHA2 456/4885 |
| US-20040102360-A1 | Combination therapy | MTOR, AKT2, PLK1 | ACLY 862/4885DRD4 4775/4885EPHA2 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.